Table 3.

False-positive report probability analysis for significant findings for the association between YTHDF2 rs3738067 A>G polymorphism and neuroblastoma susceptibility.

Genotype	Crude OR(95% CI)	P a	Statistical powerb	Prior probability
				0.25	0.1	0.01	0.001	0.0001
AG vs. AA	0.76 (0.64–0.90)	0.002	0.929	0.005	0.016	0.153	0.646	0.948
AG/GG vs. AA	0.81 (0.69–0.95)	0.010	0.986	0.030	0.086	0.508	0.913	0.991
≤ 18 months	0.75 (0.58–0.98)	0.033	0.808	0.108	0.267	0.800	0.976	0.998
Males	0.75 (0.60–0.93)	0.010	0.833	0.033	0.093	0.530	0.919	0.991
Retroperitoneal	0.69 (0.54–0.88)	0.003	0.582	0.015	0.043	0.330	0.833	0.980
Stage IV	0.68 (0.52–0.91)	0.009	0.561	0.045	0.124	0.608	0.940	0.994
Stage III+IV	0.73 (0.58–0.91)	0.006	0.765	0.021	0.061	0.416	0.878	0.986

OR, odds ratio; CI, confidence interval.

The results were in bold if the false-positive report probability <0.200.

^aChi-square test was used to calculate the genotype frequency distributions.

^bStatistical power was calculated using the number of observations in the subgroup and the OR and P-values in this table.